Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas

BMC Cancer

Siddhartha Deb²  Nicholas Jene¹  kConFab investigators³  Stephen B Fox³ 

[1] Department of Anatomical Pathology, Peter MacCallum Cancer Centre, East Melbourne, 3002, Australia

[2] Department of Pathology, University of Melbourne, Parkville, 3052, Australia

[3] Kathleen Cuningham Foundation Consortium for research into Familial Breast Cancer, Peter MacCallum Cancer Centre, East Melbourne, 3002, Australia

关键词: Familial;    Micropapillary;    BRCAX;    BRCA2;    BRCA1;    Male breast cancer;   

Others  :  1080100
DOI  :  10.1186/1471-2407-12-510

 received in 2012-05-28, accepted in 2012-10-05,  发布年份 2012

【 摘 要 】

Background

Male breast cancer (MBC) is an uncommon and relatively uncharacterised disease accounting for <1% of all breast cancers. A significant proportion occurs in families with a history of breast cancer and in particular those carrying BRCA2 mutations. Here we describe clinicopathological features and genomic BRCA1 and BRCA2 mutation status in a large cohort of familial MBCs.

Methods

Cases (n=60) included 3 BRCA1 and 25 BRCA2 mutation carries, and 32 non-BRCA1/2 (BRCAX) carriers with strong family histories of breast cancer. The cohort was examined with respect to mutation status, clinicopathological parameters including TNM staging, grade, histological subtype and intrinsic phenotype.

Results

Compared to the general population, MBC incidence was higher in all subgroups. In contrast to female breast cancer (FBC) there was greater representation of BRCA2 tumours (41.7% vs 8.3%, p=0.0008) and underrepresentation of BRCA1 tumours (5.0% vs 14.4%, p=0.0001). There was no correlation between mutation status and age of onset, disease specific survival (DSS) or other clincopathological factors. Comparison with sporadic MBC studies showed similar clinicopathological features. Prognostic variables affecting DSS included primary tumour size (p=0.003, HR:4.26 95%CI 1.63-11.11), age (p=0.002, HR:4.09 95%CI 1.65-10.12), lymphovascular (p=0.019, HR:3.25 95%CI 1.21-8.74) and perineural invasion (p=0.027, HR:2.82 95%CI 1.13-7.06). Unlike familial FBC, the histological subtypes seen in familial MBC were more similar to those seen in sporadic MBC with 46 (76.7%) pure invasive ductal carcinoma of no special type (IDC-NST), 2 (3.3%) invasive lobular carcinomas and 4 (6.7%) invasive papillary carcinoma. A further 8 (13.3%) IDC-NST had foci of micropapillary differentiation, with a strong trend for co-occurrence in BRCA2 carriers (p=0.058). Most tumours were of the luminal phenotype (89.7%), with infrequent HER2 (8.6%) and basal (1.7%) phenotype tumours seen.

Conclusion

MBC in BRCA1/2 carriers and BRCAX families is different to females. Unlike FBC, a clear BRCA1 phenotype is not seen but a possible BRCA2 phenotype of micropapillary histological subtype is suggested. Comparison with sporadic MBCs shows this to be a high-risk population making further recruitment and investigation of this cohort of value in further understanding these uncommon tumours.

【 授权许可】

   
2012 Deb et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Weiss JR, Moysich KB, Swede H: Epidemiology of male breast cancer. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2005, 14(1):20-26.
• [2]Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, Bartlett JM, Gelmon K, Nahleh Z, Bergh J, et al.: Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 2010, 28(12):2114-2122.
• [3]SEER Database. http://seer.cancer.gov/ webcite
• [4]Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA: a cancer journal for clinicians 2009, 59(4):225-249.
• [5]Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer statistics, 2004. CA: a cancer journal for clinicians 2004, 54(1):8-29.
• [6]Nilsson C, Holmqvist M, Bergkvist L, Hedenfalk I, Lambe M, Fjallskog ML: Similarities and differences in the characteristics and primary treatment of breast cancer in men and women - a population based study (Sweden). Acta oncologica (Stockholm, Sweden) 2011, 50(7):1083-1088.
• [7]Anderson WF, Jatoi I, Tse J, Rosenberg PS: Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol 2010, 28(2):232-239.
• [8]Foerster R, Foerster FG, Wulff V, Schubotz B, Baaske D, Wolfgarten M, Kuhn WC, Rudlowski C: Matched-pair analysis of patients with female and male breast cancer: a comparative analysis. BMC cancer 2011, 11:335. BioMed Central Full Text
• [9]Basham VM, Lipscombe JM, Ward JM, Gayther SA, Ponder BA, Easton DF, Pharoah PD: BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast cancer research: BCR 2002, 4(1):R2. BioMed Central Full Text
• [10]Evans DG, Bulman M, Young K, Gokhale D, Lalloo F: High detection rate for BRCA2 mutations in male breast cancer families from North West England. Familial cancer 2001, 1(3–4):131-133.
• [11]Thompson D, Easton D: Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001, 68(2):410-419.
• [12]Fackenthal JD, Marsh DJ, Richardson AL, Cummings SA, Eng C, Robinson BG, Olopade OI: Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Gen 2001, 38(3):159-164.
• [13]Anelli A, Anelli TF, Youngson B, Rosen PP, Borgen PI: Mutations of the p53 gene in male breast cancer. Cancer 1995, 75(9):2233-2238.
• [14]Wasielewski M, den Bakker MA, van den Ouweland A, Meijer-van Gelder ME, Portengen H, Klijn JG, Meijers-Heijboer H, Foekens JA, Schutte M: CHEK2 1100delC and male breast cancer in the Netherlands. Breast Cancer Res Treat 2009, 116(2):397-400.
• [15]Evans DB, Crichlow RW: Carcinoma of the male breast and Klinefelter's syndrome: is there an association? CA: a cancer journal for clinicians 1987, 37(4):246-251.
• [16]Brinton LA, Richesson DA, Gierach GL, Lacey JV Jr, Park Y, Hollenbeck AR, Schatzkin A: Prospective evaluation of risk factors for male breast cancer. J Nat Cancer Inst 2008, 100(20):1477-1481.
• [17]Sasco AJ, Lowenfels AB, Pasker-de Jong P: Review article: epidemiology of male breast cancer. A meta-analysis of published case–control studies and discussion of selected aetiological factors. Int J Cancer J Int du, cancer 1993, 53(4):538-549.
• [18]Anderson WF, Althuis MD, Brinton LA, Devesa SS: Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat 2004, 83(1):77-86.
• [19]Mann GJ, Thorne H, Balleine RL, Butow PN, Clarke CL, Edkins E, Evans GM, Fereday S, Haan E, Gattas M, et al.: Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res: BCR 2006, 8(1):R12. BioMed Central Full Text
• [20]Lum A, Le Marchand L: A simple mouthwash method for obtaining genomic DNA in molecular epidemiological studies. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 1998, 7(8):719-724.
• [21]kConFab Biospecimen Protocol. http://www.kconfab.org/epidemiology/biospecimen_protocol.html webcite
• [22]Hogervorst FB, Nederlof PM, Gille JJ, McElgunn CJ, Grippeling M, Pruntel R, Regnerus R, van Welsem T, van Spaendonk R, Menko FH, et al.: Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res 2003, 63(7):1449-1453.
• [23]kConFab Classification of BRCA1 and BRCA2 Mutations. http://www.kconfab.org/progress/mutations.asp webcite
• [24]Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, et al.: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clinical Cancer Res: an official journal of the American Association for Cancer Research 2004, 10(16):5367-5374.
• [25]Leake R, Barnes D, Pinder S, Ellis I, Anderson L, Anderson T, Adamson R, Rhodes T, Miller K, Walker R: Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC. J Clin Pathol 2000, 53(8):634-635.
• [26]Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25(1):118-145.
• [27]Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, et al.: Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clinical Cancer Res: an official journal of the American Association for Cancer Research 2005, 11(14):5175-5180.
• [28]Arslan UY, Oksuzoglu B, Ozdemir N, Aksoy S, Alkis N, Gok A, Kaplan MA, Gumus M, Berk V, Uncu D, et al.: Outcome of non-metastatic male breast cancer: 118 patients. Med Oncol (Northwood, London, England) 2011, 29(2):554-60.
• [29]Bourhafour M, Belbaraka R, Souadka A, M'Rabti H, Tijami F, Errihani H: Male breast cancer: a report of 127 cases at a Moroccan institution. BMC Res notes 2011, 4:219. BioMed Central Full Text
• [30]Cutuli B, Le-Nir CC, Serin D, Kirova Y, Gaci Z, Lemanski C, De Lafontan B, Zoubir M, Maingon P, Mignotte H, et al.: Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. Critical reviews in oncology/hematology 2010, 73(3):246-254.
• [31]Ding YC, Steele L, Kuan CJ, Greilac S, Neuhausen SL: Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. Breast Cancer Res Treatment 2011, 126(3):771-778.
• [32]Evans DG, Bulman M, Young K, Howard E, Bayliss S, Wallace A, Lalloo F: BRCA1/2 mutation analysis in male breast cancer families from North West England. Familial cancer 2008, 7(2):113-117.
• [33]Johansson I, Nilsson C, Berglund P, Strand C, Jonsson G, Staaf J, Ringner M, Nevanlinna H, Barkardottir RB, Borg A, et al.: High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer. Breast cancer research and treatment 2011, 129(3):747-760.
• [34]Kiluk JV, Lee MC, Park CK, Meade T, Minton S, Harris E, Kim J, Laronga C: Male breast cancer: management and follow-up recommendations. The Breast J 2011, 17(5):503-509.
• [35]Liukkonen S, Saarto T, Maenpaa H, Sjostrom-Mattson J: Male breast cancer: a survey at the Helsinki University Central Hospital during 1981–2006. Acta Oncol(Stockholm, Sweden) 2010, 49(3):322-327.
• [36]Miao H, Verkooijen HM, Chia KS, Bouchardy C, Pukkala E, Laronningen S, Mellemkjaer L, Czene K, Hartman M: Incidence and outcome of male breast cancer: an international population-based study. J Clin Oncol 2011, 29(33):4381-4386.
• [37]Nahleh ZA, Srikantiah R, Safa M, Jazieh AR, Muhleman A, Komrokji R: Male breast cancer in the veterans affairs population: a comparative analysis. Cancer 2007, 109(8):1471-1477.
• [38]Ottini L, Rizzolo P, Zanna I, Falchetti M, Masala G, Ceccarelli K, Vezzosi V, Gulino A, Giannini G, Bianchi S, et al.: BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy. Breast Cancer Res Treat 2009, 116(3):577-586.
• [39]Shaaban AM, Ball GR, Brannan RA, Cserni G, Benedetto AD, Dent J, Fulford L, Honarpisheh H, Jordan L, Jones JL, et al.: A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. Breast Cancer Res Treat 2011, 33(3):949-58.
• [40]Zhou FF, Xia LP, Wang X, Guo GF, Rong YM, Qiu HJ, Zhang B: Analysis of prognostic factors in male breast cancer: a report of 72 cases from a single institution. Chinese J Cancer 2010, 29(2):184-188.
• [41]Loughrey M, Provan PJ, Byth K, Balleine RL: Histopathological features of 'BRCAX' familial breast cancers in the kConFab resource. Pathology 2008, 40(4):352-358.
• [42]Marchio C, Iravani M, Natrajan R, Lambros MB, Savage K, Tamber N, Fenwick K, Mackay A, Senetta R, Di Palma S, et al.: Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. J Pathol 2008, 215(4):398-410.
• [43]Johansen Taber KA, Morisy LR, Osbahr AJ 3rd, Dickinson BD: Male breast cancer: risk factors, diagnosis, and management (Review). Oncol reports 2010, 24(5):1115-1120.
• [44]Marchal F, Salou M, Marchal C, Lesur A, Desandes E: Men with breast cancer have same disease-specific and event-free survival as women. Annals Surg Oncol 2009, 16(4):972-978.
• [45]Ottini L, Silvestri V, Rizzolo P, Falchetti M, Zanna I, Saieva C, Masala G, Bianchi S, Manoukian S, Barile M, et al.: Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy. Breast Cancer Res Treat 2012, 134(1):411-418.
• [46]Tavassoli FA, Devilee P, Organization WH, Cancer IAR: Pathology and genetics of tumours of the breast and female genital organs. IARC Press, Lyon, France; 2003.
• [47]Ottini L, Masala G, D'Amico C, Mancini B, Saieva C, Aceto G, Gestri D, Vezzosi V, Falchetti M, De Marco M, et al.: BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Cancer Res 2003, 63(2):342-347.
• [48]Fentiman IS, Fourquet A, Hortobagyi GN: Male breast cancer. Lancet 2006, 367(9510):595-604.
• [49]Ouriel K, Lotze MT, Hinshaw JR: Prognostic factors of carcinoma of the male breast. Surg gynecol Obstet 1984, 159(4):373-376.
• [50]Nassar H: Carcinomas with micropapillary morphology: clinical significance and current concepts. Adv Anatomic Pathol 2004, 11(6):297-303.
• [51]Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storfer-Isser A, et al.: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Nat Cancer Inst 1998, 90(15):1138-1145.
• [52]Cetintas SK, Kurt M, Ozkan L, Engin K, Gokgoz S, Tasdelen I: Factors influencing axillary node metastasis in breast cancer. Tumori 2006, 92(5):416-422.
• [53]Duraker N, Caynak ZC, Turkoz K: Perineural invasion has no prognostic value in patients with invasive breast carcinoma. Breast (Edinburgh, Scotland) 2006, 15(5):629-634.
• [54]Ozaki H, Hiraoka T, Mizumoto R, Matsuno S, Matsumoto Y, Nakayama T, Tsunoda T, Suzuki T, Monden M, Saitoh Y, et al.: The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection. Surg Today 1999, 29(1):16-22.
• [55]Masieri L, Lanciotti M, Nesi G, Lanzi F, Tosi N, Minervini A, Lapini A, Carini M, Serni S: Prognostic role of perineural invasion in 239 consecutive patients with pathologically organ-confined prostate cancer. Urologia internationalis 2010, 85(4):396-400.
• [56]Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium J Nat Cancer Inst 1999, 91(15):1310-1316.
• [57]Easton DF, Steele L, Fields P, Ormiston W, Averill D, Daly PA, McManus R, Neuhausen SL, Ford D, Wooster R, et al.: Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Human Genet 1997, 61(1):120-128.
• [58]Kirchhoff T, Kauff ND, Mitra N, Nafa K, Huang H, Palmer C, Gulati T, Wadsworth E, Donat S, Robson ME, et al.: BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clinical Cancer Res: an official journal of the American Association for Cancer Research 2004, 10(9):2918-2921.
• [59]Willems AJ, Dawson SJ, Samaratunga H, De Luca A, Antill YC, Hopper JL, Thorne HJ: Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation. Clinical Cancer Res: an official journal of the American Association for Cancer Research 2008, 14(10):2953-2961.